Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - agents antinéoplasiques - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - mélanome - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Canada - français - Health Canada

bristol-myers squibb canada - nivolumab - solution - 10mg - nivolumab 10mg - antineoplastic agents

Canada - français - Health Canada

bristol-myers squibb canada - nivolumab - solution - 10mg - nivolumab 10mg - antineoplastic agents

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

norgine sa-nv - chlorure de sodium 0,1754 g; chlorure de potassium 0,0251 g; macrogol 6,563 g; bicarbonate de sodium 0,0893 g - poudre pour solution buvable - 6,9 g - macrogol 3.350 6563 mg; chlorure de potassium 25.1 mg; chlorure de sodium 175.4 mg; bicarbonate de sodium 89.3 mg - macrogol, combinations

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

norgine sa-nv - bicarbonate de sodium 0,1786 g; chlorure de sodium 0,3508 g; chlorure de potassium 0,0502 g; macrogol 13,125 g - poudre pour solution buvable - 13,7 g - macrogol 3.350 13125 mg; chlorure de potassium 50.2 mg; bicarbonate de sodium 178.6 mg; chlorure de sodium 350.8 mg - macrogol, combinations

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intergal pharma ireland ltd. - macrogol 6,563 g; bicarbonate de sodium 0,0893 g; chlorure de potassium 0,0251 g; chlorure de sodium 0,1754 g - poudre pour solution buvable - 6.9 g - macrogol 3.350 6563 mg; chlorure de potassium 25.1 mg; chlorure de sodium 175.4 mg; bicarbonate de sodium 89.3 mg - macrogol, combinations

Canada - français - Health Canada

professional health products - spigélie vermifuge; adonis printanière; iodure de baryum; quinquina; scille - liquide - 4d; 4d; 6d; 3d; 4d - spigélie vermifuge 4d; adonis printanière 4d; iodure de baryum 6d; quinquina 3d; scille 4d - homeopathic products

Canada - français - Health Canada

bimeda-mtc animal health inc - dextrose; saindoux; huile de noix de coco; acétate de potassium; acétate de sodium - pâte - 16.75%; 15.46%; 13.22%; 11.59%; 11.59% - dextrose 16.75%; saindoux 15.46%; huile de noix de coco 13.22%; acétate de potassium 11.59%; acétate de sodium 11.59% - porcs

Canada - français - Health Canada

citadel animal health - dextrose; saindoux; huile de noix de coco; acétate de potassium; acétate de sodium - pâte - 16.75%; 15.46%; 13.22%; 11.59%; 11.59% - dextrose 16.75%; saindoux 15.46%; huile de noix de coco 13.22%; acétate de potassium 11.59%; acétate de sodium 11.59% - porcs